Cyril RONCO, PhD, HDR
Team Leader of Drug Advances & Innovations Research Group
Head of Medicinal & Bioorganic Chemistry Master Track of Nice
Member of Institut Universitaire de France
Member of A. von Humboldt Foundation
Co-founder and active Board Member of Roca Therapeutics
Co-founder and active Board Member of BiPER Therapeutics
Institute of Chemistry of Nice (ICN)
UMR7272 Université Côte d'Azur – CNRS
28 avenue Valrose 06100 Nice France
cyril.ronco[a]univ-cotedazur.fr
 |
https://orcid.org/0000-0002-9023-5940 |
 |
https://www.researchgate.net/profile/Cyril-Ronco |
 |
https://scholar.google.com/citations?user=E6FNW0gAAAAJ |
CURRICULUM VITAE:
2023 – Member of Institut Universitaire de France
2021 – Cofundation of BiPER Therapeutics
2020 – Cofundation of Roca Therapeutics
2019 – Associate Professor at UniCA
2014 – Assistant Professor at UNS
2011 – Member of the Alexander von Humboldt Foundation
2010 – PhD with honours in Organic Chemistry – Université de Rouen
2007 – MS in Organic & Bioorganic Chemistry – Université Blaise Pascal
2006 – MS in Chemistry – ENSCCF Engineer High School
AWARDS AND HONOURS:
2023 – Nomination at the Institut Universitaire de France
2023 – UCA Excellency Award – University Côte d’Azur
2023 – Prix Galien USA – Best Startup Category Nominee (Team Award)
2022 – I-Lab National Innovation Award – BPI France
2022 – UCA Excellency Award – University Côte d’Azur
2021 – I-Lab National Innovation Award – BPI France (Team Award)
2021 – 2 x UCA Excellency Awards – University Côte d’Azur
2021 – Matwin International Innovation Competition Laureate (Team Award)
2019 – Award of Young researcher in Medicinal Chemistry of the Société de Chimie Thérapeutique
2018 – Sanofi Innovation Award (Team Award)
2011 – Fellow and 2-years excellence postdoctoral grant of the Alexander von Humboldt Foundation
KEY PUBLICATIONS:
O. Grytsai†, M. Dufies†, J. Le Du, L. C. P. Gonçalves, L. Mateo, S. Lacas-Gervais, Y. Cao, L. Demange, G. Pages*, R. Benhida*, C. Ronco*. “Optimized ELR+CXCL-CXCR1/2 Pathway Inhibitor: A Potent Solution for Tumor Growth and Angiogenesis Suppression”. ACS. Med. Chem. Lett. 2024, asap. – Selected for journal Front Cover. doi: 10.1021/acsmedchemlett.4c00053
O. Grytsai, N. Hamouda-Tekaya, T. Botton, S. Roсchi, R. Benhida*, C. Ronco*. “Design, Synthesis and Biological Evaluation of Novel Anticancer Amidinourea Analogues via Unexpected 1,3,5-Triazin-2-one Ring Opening”. ChemMedChem, 2024, 19, e202300493. doi: 10.1002/cmdc.202300493. - Selected as « V.I.P. Paper ». Highlighted in Chemistry Views.
C. Montemagno, A. Jacquel, C. Pandiani, O. Rastoin, R. Dawaliby, T. Schmit, M. Bourgoin, H. Palenzuela, A.-L. Rossi, J. Durivault, W. Echavidre, D. Ambrosetti, F. Luciano, D. Borchiellini, J. Le Du, L. C. P. Gonçalves, P. Auberger, R. Benhida, B. Benoit, C. Ronco, G. Pagès*, M. Dufies*. “Unveiling CXCR2 as a Promising Therapeutic Nexus in Renal Cell Carcinoma: Exploring the Immunotherapeutic Paradigm Shift through its Inhibition by RCT001”, J. Exp. Clin. Cancer. Res. 2024, 43, 86. doi: 10.1186/s13046-024-02984-2
O. Grytsai, I. Myroskova, S. Rocchi*, C. Ronco*, R. Benhida*. “Biguanides drugs: past success stories and promising future for cancer therapy”. European Journal of Medicinal Chemistry 2021, 224, 113726. doi: 10.1016/j.ejmech.2021.113726.
O. Grytsai†, O. Valiashko†, M. Penco-Campillo, M. Dufies, A. Hagege, S. Martial, G. Pagès, C. Ronco*, R. Benhida*. “Synthesis and biological evaluation of 3-amino-1,2,4-triazole derivatives as potential anticancer compounds”. Bioorganic Chemistry 2020, 104, 104271. doi: 10.1016/j.bioorg.2020.104271